Please login to the form below

Not currently logged in
Email:
Password:

JAK1 inhibitor

This page shows the latest JAK1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis

Pfizer’s Cibinqo granted FDA approval for adults with moderate-to-severe atopic dermatitis

Cibinqo is a once-daily, oral Janus kinase 1 (JAK1) inhibitor used in adult patients living with moderate-to-severe atopic dermatitis who have not yet found relief in currently available

Latest news

More from news
Approximately 1 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Sales are projected at $1.589bn in 2024. 5. Filgotinib from Gilead/Galapagos is an oral JAK1 inhibitor in regulatory review in the US, EU and Japan for rheumatoid arthritis Overactivation ... It will face competition mainly from generic statins and PCSK9

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    is its experimental JAK1 inhibitor filgotinib for rheumatoid arthritis.

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    Upadacitinib, from AbbVie, treats rheumatoid arthritis. Upadacitinib is an orally dosed inhibitor of an intracellular target called JAK1. ... The first-in-class inhibitor of hypoxia- inducible factor-prolyl hydroxylase, or HIFPH, was approved in December

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... t the only oral JAK inhibitor developer with its eye on that particular prize.

  • Deal Watch December 2015 Deal Watch December 2015

    Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's disease . ... 825. Takeda (Respiratory). AstraZeneca. Acquisition - asset. AZ buys Takeda global respiratory business including PDE 4

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
foxandcat.online

We help communications teams to thrive under pressure. Here at fox&cat, we help all kinds of teams to fight all...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....